Q2 2023 Earnings Forecast for PDS Biotechnology Co. (NASDAQ:PDSB) Issued By HC Wainwright

Posted by Defense World Staff on May 19th, 2023

PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) – Equities research analysts at HC Wainwright lowered their Q2 2023 earnings estimates for PDS Biotechnology in a research report issued to clients and investors on Monday, May 15th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.39) per share for the quarter, down from their prior forecast of ($0.25). HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q3 2023 earnings at ($0.42) EPS, Q4 2023 earnings at ($0.46) EPS, FY2023 earnings at ($1.57) EPS, FY2024 earnings at ($1.26) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.31) EPS and FY2027 earnings at ($1.26) EPS.

Several other research firms have also issued reports on PDSB. StockNews.com assumed coverage on shares of PDS Biotechnology in a research report on Thursday. They issued a “sell” rating for the company. B. Riley reissued a “buy” rating and issued a $12.00 price target on shares of PDS Biotechnology in a research report on Wednesday, March 29th.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $7.40 on Thursday. PDS Biotechnology has a 12-month low of $2.89 and a 12-month high of $13.65. The company has a quick ratio of 7.79, a current ratio of 16.46 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $228.07 million, a PE ratio of -5.10 and a beta of 2.09. The firm has a 50-day moving average price of $6.35 and a 200 day moving average price of $7.89.

PDS Biotechnology (NASDAQ:PDSB – Get Rating) last released its earnings results on Tuesday, March 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.37).

Institutional Trading of PDS Biotechnology

Several hedge funds have recently modified their holdings of PDSB. Oppenheimer & Co. Inc. increased its holdings in shares of PDS Biotechnology by 78.6% during the first quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the company’s stock worth $155,000 after buying an additional 11,000 shares in the last quarter. BlackRock Inc. increased its holdings in shares of PDS Biotechnology by 1.0% during the first quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock worth $2,697,000 after buying an additional 4,199 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of PDS Biotechnology by 99.9% in the first quarter. Dimensional Fund Advisors LP now owns 69,628 shares of the company’s stock valued at $431,000 after purchasing an additional 34,797 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of PDS Biotechnology by 7.8% in the first quarter. Vanguard Group Inc. now owns 1,093,885 shares of the company’s stock valued at $6,771,000 after purchasing an additional 79,025 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of PDS Biotechnology by 49.5% in the first quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock valued at $4,117,000 after purchasing an additional 220,300 shares in the last quarter. Institutional investors and hedge funds own 18.21% of the company’s stock.

About PDS Biotechnology

(Get Rating)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.